Investors and market participants can look forward to the unveiling of Pacira BioSciences (NASDAQ: PCRX) third quarter financial results on Wednesday 6th November 2024. This important update will be made available after market close.
It appears that the business is on the verge of revealing their estimated $0.70 profit per share for the quarter, as well as their total revenue of $169.67 million for this specific period, according to financial experts on Wall Street.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $692.72 million. Additionally, they are expecting the company to report profit of $3.01 per share for the full year 2024.
In comparison to the same quarter of the prior year, the company's financial statement showcased a per share of income of $0.72. This was credited to the company's total revenue, which reached an impressive $163.93 million in that particular timeframe.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.89 | +14.1% | 178.02 M | +5.0% |
| Q1 2024 | $0.62 | +17.0% | 167.12 M | +4.2% |
| Q4 2023 | $0.89 | +11.3% | 181.24 M | +5.4% |
| Q3 2023 | $0.72 | +12.5% | 163.93 M | -2.1% |
| Q2 2023 | $0.78 | +52.9% | 169.47 M | +0.0% |
| *Growth on year-over-year basis | ||||
PCRX will host a conference call with investment community on 6th November 2024 at 04:30 PM eastern time to discuss the financial results.
Throughout Friday's trading, Pacira BioSciences (PCRX) shares fluctuated between $16.40 and $17.07, with a trading volume of 431.70 thousand shares. The stock ended the regular trading session at $16.57, reflecting decrease of 0.18 percent.
